CMTX BIOTECH INC
Kings Park, NY · Founded 2019 · CIK 0001810627 · Biotech · Private
Therapeutic drug formulations for clinical stage candidates
cmtxbiotech.com →- Grants
- $3.4M
- 8 awards
- Sector median: 1
- Raised
- $500K
- 1 Form D · May 2020
- 77 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 1 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome | $426,744 | |
| Federal grant | Department of Health and Human Services · Phase I · Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome | $426,744 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia | $376,752 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel Small Molecule Drug Candidate for the Prevention of Bronchopulmonary Dysplasia | $376,752 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury | $299,993 | |
| Federal grant | Department of Health and Human Services · Phase II · Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome | $887,354 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury | $295,715 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Small Molecule for the Prevention of Hemorrhagic Cystitis | $349,687 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2125 | Apricity Therapeutics | — | — |
| 2126 | Lygos, Inc. | — | $41M |
| 2127 | SENSORIUM THERAPEUTICS INC | — | $39M |
| 2128 | CMTX BIOTECH INC | — | $500K |
| 2129 | ProMIS Neurosciences Inc. | — | $39M |
| 2130 | CASI Pharmaceuticals, Inc. | — | $35M |
| 2131 | BLUE THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James KeaneDirector · Executive Officer · Promoter
- Joseph ScadutoDirector · Executive Officer · Promoter
Patents
- Methods Of Treating Charcot-marie-tooth Diseasegranted
- Methods Of Treating Illnesses Caused By Coronavirus, Swine Flu And Avian Fluapplication
- Methods Of Treating Illnesses Caused By Coronavirus, Swine Flu And Avian Fluapplication
- Methods Of Treating Charcot-marie-tooth Diseaseapplication
- Methods Of Treating Illnesses Caused By Coronavirus, Swine Flu And Avian Fluapplication
- Methods Of Preventing Or Treating Vesicant-induced Injuryapplication
- Methods For Treating Charcot-marie-tooth Diseaseapplication
- Methods Of Preventing Or Treating Vesicant-induced Injuryapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.